Rep. Adams Urges Supreme Court to Maintain Access to Mifepristone in Louisiana v. FDA Decision

Washington, D.C. — Today, Congresswoman Alma S. Adams, Ph.D. (NC-12) commented on the Supreme Court’s emergency stay of the Louisiana v. Food and Drug Administration (FDA) Fifth Circuit decision regarding access to the drug Mifepristone.

“On Monday, May 4, I filed an amicus brief with over 250 of my Democratic colleagues in Congress urging them to overturn the decision of the Fifth Circuit.

“States cannot be allowed to walk back protections that women have fought to secure for decades.

“The FDA’s rigorous congressionally mandated, evidence-based process for drug regulations has approved Mifepristone’s use and their studies confirm the drug is safe regardless of how it is dispensed. Reinstating in-person dispensation requirements for Mifepristone severely limits access to the most common method of early, safe abortion.

“I have spent my career fighting for women’s access to safe and effective reproductive healthcare. For 50 years, women have been able to take control of their own bodies, and since the Dobbs decision, that control is being taken away.

“Women deserve healthcare, and abortion care is healthcare. This lower court decision cannot stand.”